Cingulate Inc. (CINGW)

Current Report Filed: 2026-05-14

Key Insights

Cingulate announced Q1 2026 financial results and business update on May 14, 2026, providing investors with current operational performance and forward-looking guidance.
The company is classified as an emerging growth company, indicating it may have reduced regulatory compliance burdens and access to scaled disclosure requirements under securities laws.
The filing contains no material agreements, leadership changes, or significant corporate events—it is a routine quarterly earnings announcement with limited substantive disclosures beyond the press release reference.

Quarterly Report Filed: 2026-05-14

Key Insights

The filing appears to be a structural/XML metadata document rather than a complete 10-Q with substantive financial data, operational metrics, or management discussion - making it impossible to assess actual Q1 2026 financial performance or trends.
Multiple financing transactions are referenced (Series A Convertible Preferred Stock in February and March 2026, various note purchase agreements, ATM agreements) suggesting the company is actively raising capital, which may indicate liquidity needs or business expansion plans.
The document shows debt instruments from multiple sources (Streetville Capital, Avondale Capital) with varying maturity dates (2024-2026), indicating complex capital structure that investors should monitor for refinancing risk and dilution effects.
Presence of warrant and preferred stock conversion mechanisms creates significant dilution potential for common shareholders that requires detailed analysis of conversion terms and exercise probabilities not visible in this metadata extract.

Current Report Filed: 2026-04-02

Key Insights

Cingulate Inc. (CINGW) appointed Zhanpeng 'Frederick' Jiang to its Board of Directors, effective immediately. Jiang will serve as a Class I director until the 2028 Annual Meeting of Stockholders.
Jiang was appointed to serve on the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee of the Board.
The Board determined that Jiang is independent as defined by Nasdaq listing rules. Jiang was granted a stock option and will receive annual cash retainers for his board and committee service.

Current Report Filed: 2026-03-24

Key Insights

Cingulate Inc. has entered into an At-the-Market (ATM) equity offering program, allowing it to sell up to $100 million of its common stock over time.
Shareholders have approved the issuance of common stock upon conversion of Series A Convertible Preferred Stock and/or the exercise of warrants, as per the company's securities purchase agreement dated January 27, 2026.
The company has obtained shareholder approval to adjourn the special meeting if necessary to permit further solicitation and vote of proxies, though this was ultimately deemed unnecessary.

Current Report Filed: 2026-03-18

Key Insights

Cingulate Inc. announced positive financial results for the year ended December 31, 2025, indicating the company's operations and performance are improving.
The company received a Notice of Allowance from the USPTO for a patent on its lead asset CTx-1301, which will provide patent protection until 2042 and strengthen its intellectual property portfolio.
As an emerging growth company, Cingulate's adoption of new financial accounting standards could impact future financial reporting and investor analysis.

Annual Report Filed: 2026-03-18

Key Insights

The company has experienced significant growth in its clinical operations, drug manufacturing, and personnel expenses over the past two years, indicating a focus on advancing its product pipeline.
Cingulate has entered into multiple financing agreements, including with Avondale Capital LLC and Streetville Capital LLC, which could provide additional capital to support its operations and development efforts.
The company has been actively issuing warrants and convertible securities to investors, which could lead to future dilution of existing shareholders if exercised.

Current Report Filed: 2026-02-17

Key Insights

Cingulate Inc. (CING) issued 25,786 shares of common stock to a lender in exchange for a portion of its debt, indicating the company is actively managing its capital structure.
The company appointed Jeff Hargroves to its Board of Directors, adding an independent director with potential industry expertise to the leadership team.
Cingulate announced the successful completion of the second and final closing of its private placement, raising an additional $5.5 million in gross proceeds, for a total of approximately $12 million raised.

Insider Trading Filed: 2026-02-10

Key Insights

The reporting person, Matthew Brams, who is the EVP and Chief Medical Officer of Cingulate Inc. (CING), acquired 1,946 shares of common stock and 1,556 warrants in the company's private placement transaction.
The acquisition of shares and warrants by an executive officer suggests positive sentiment towards the company's future prospects.
The timing of the transaction, which occurred on February 6, 2026, is significant as it represents a recent investment by an insider in the company.

Insider Trading Filed: 2026-02-10

Key Insights

Insider Shane J. Schaffer, who is the CEO and a director, purchased 6,809 shares of Cingulate Inc. (CING) at $5.04 per share in a private placement, indicating his confidence in the company.
The reporting person also holds warrants to purchase an additional 5,447 shares of Cingulate, further demonstrating his alignment with shareholders.
The private placement transaction was disclosed in a previous Form 8-K filing, providing transparency around the company's capital raising activities.

Insider Trading Filed: 2026-02-10

Key Insights

Jennifer L. Callahan, the SVP and CFO of Cingulate Inc., acquired 4,864 shares of the company's common stock at $5.04 per share, indicating her confidence in the company's prospects.
Callahan also acquired 3,891 warrants to purchase common stock at $5.04, exercisable upon the company obtaining stockholder approval for the private placement disclosed in the previous Form 8-K filing.
The insider buying activity suggests that the company's management is optimistic about the company's future performance and growth potential.

Insider Trading Filed: 2026-02-10

Key Insights

The reporting person, Peter J. Werth, acquired 19,455 shares of Cingulate Inc. (CING) common stock and 15,564 warrants to purchase common stock in a private placement transaction on February 6, 2026.
The reporting person's beneficial ownership has increased to 117,449 shares, including an indirect ownership of 117,449 shares and 15,564 warrants through Werth Family Investment Associates LLC.
The warrants are exercisable upon the issuer obtaining stockholder approval of the private placement, as required by the Nasdaq rules, and have an expiration date of 36 months after the exercise date.

Current Report Filed: 2026-02-06

Key Insights

Cingulate Inc. issued over 360,000 shares of common stock between January 6 and February 5, 2026 to repay debt, indicating the company is actively managing its capital structure.
The company completed a $6.5 million portion of a previously announced $12 million private placement, providing additional capital to fund operations.
Cingulate is an emerging growth company, which may provide more flexibility in financial reporting and accounting standards compliance.

Current Report Filed: 2026-01-28

Key Insights

Cingulate Inc. raised approximately $12 million through a private placement of common stock, preferred stock, and warrants. This capital raise will provide funding to support the company's operations and development activities.
Certain officers, directors, and affiliates of Cingulate participated in the private placement, aligning their interests with those of the company and other investors.
The company has agreed to file a registration statement with the SEC to register the resale of the securities issued in the private placement, providing liquidity for the investors.

Current Report Filed: 2026-01-15

Key Insights

Cingulate Inc. increased the maximum aggregate offering price of shares of its common stock under the At The Market Offering Agreement from $23.5 million to $31.9 million, allowing the company to raise more capital through this program.
The company has already sold $15.1 million worth of common stock under the At The Market Offering Agreement prior to this increase.
Cingulate Inc. filed a new prospectus supplement for an additional $8.8 million of common stock that can be sold under the At The Market Offering Agreement.

Current Report Filed: 2026-01-02

Key Insights

Cingulate Inc. has issued a significant amount of common stock to lenders in exchange for debt repayment, indicating the company is actively managing its capital structure.
The company has issued stock at various prices ranging from $3.39 to $4.13 per share, suggesting the stock price has been volatile during this period.
The exemption from registration under Section 3(a)(9) of the Securities Act for these stock issuances indicates the company is leveraging a provision that allows for the exchange of securities without registration.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information